We are live on ! Find out more

Design Therapeutics

DSGN

Market cap $954M

15.25 USD

-0.34

2.18%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

15.25

0.00

0%

1 day

-2.18%

5 days

-2.62%

1 month

28.37%

3 months

37.39%

6 months

46.07%

Year to date

67.58%

1 year

188.28%

5 years

-12.46%

10 years

-63.24%

About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Employees: 55

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 40%

Neutral 60%

Negative 0%

24/7 Wall Street

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech sitting on pivotal pipeline data have all landed on analysts' radars this week for very different reasons.

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong financial runway CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio.

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1).

Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1

Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible.

Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m.

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript

Investors Business Daily

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost it all.

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026

See News Rankings

Price charts implemented using Lightweight Charts™